Migraine headache treatment in the USA

Understanding migraine

Migraine is a common and potentially severe chronic, disabling disease. In the U.S., roughly 30 million adults live with migraine, about 80% of them women. More than 75% of patients report one to 14 headaches per month, and over half of these attacks force bed rest.

Estimates range as high as 112 million bedridden days a year, with a cost to employers calculated at $14 billion annually. Migraine also affects children: about 10% of school-age children experience it, and half of all sufferers have their first attack before age 12.

Why both nerves matter

In 90% of cases, migraine and craniofacial neuralgia involve both the trigeminal and greater occipital nerves. In the clinic's experience, treating one nerve without the other did not prove helpful, while simultaneous treatment resulted in the longest discontinuation of migraine.

Central to the approach is rebalancing the autonomic nervous system, modulating the sympathetic and parasympathetic branches to interrupt the neurovascular cascade that underlies a migraine attack.

What sets this approach apart

Patients undergo a single treatment session in which the formula is carefully administered to targeted nerve branches. With no need for premedication or intravenous access, patients can resume daily activities right away.

In the clinic's experience, over 95% of patients experience relief from migraine and facial pain after one session, with the remaining few benefiting from free touch-up treatments as needed.

Patients travel to us from

• Corona, CA
• San Diego, CA
• Los Angeles, CA
• San Francisco, CA
• New York, NY
• Miami, FL
• Houston, TX
• Dallas, TX
• Scottsdale, AZ
• Washington, D.C.
• Chicago, IL
• Boston, MA
• New Jersey
• Atlanta, GA
• Baltimore, MD

Common questions

Individual results vary. Outcomes described on this page reflect the clinic's own experience and published research. See our Disclaimer.